Everolimus in advanced, progressive, well‐differentiated, non‐functional neuroendocrine tumors: RADIANT‐4 lung subgroup analysis

In the phase III RADIANT‐4 study, everolimus improved median progression‐free survival (PFS) by 7.1 months in patients with advanced, progressive, well‐differentiated (grade 1 or grade 2), non‐functional lung or gastrointestinal neuroendocrine tumors (NETs) vs placebo (hazard ratio, 0.48; 95% confid...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cancer Sci
Main Authors: Fazio, Nicola, Buzzoni, Roberto, Delle Fave, Gianfranco, Tesselaar, Margot E., Wolin, Edward, Van Cutsem, Eric, Tomassetti, Paola, Strosberg, Jonathan, Voi, Maurizio, Bubuteishvili‐Pacaud, Lida, Ridolfi, Antonia, Herbst, Fabian, Tomasek, Jiri, Singh, Simron, Pavel, Marianne, Kulke, Matthew H., Valle, Juan W., Yao, James C.
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2017
Teme:
Original Articles
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5765303/
https://ncbi.nlm.nih.gov/pubmed/29055056
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13427
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki